RITA Medical Systems Names New CFO

Apr 16, 2001, 01:00 ET from RITA Medical Systems, Inc.

    MOUNTAIN VIEW, Calif., April 16 /PRNewswire/ --
 RITA Medical Systems, Inc. (Nasdaq: RITA) today announced that
 Donald J. Stewart has joined the company as Vice President,
 Finance & Administration and Chief Financial Officer.  Stewart will report
 directly to Barry Cheskin, RITA's President and Chief Executive Officer.
 Earlier this year the Company announced Marilynne Solloway's intention to
 retire and the initiation of a search for her replacement, and the Company is
 pleased to announce the successful outcome of that search.
     Stewart comes to RITA from Abaxis, Inc., a medical device company
 manufacturing point-of-care blood analysis systems.  Stewart spent three years
 at Abaxis as Vice President, Finance & Administration, Chief Financial Officer
 and Secretary.  Previously he served as Vice President, Finance &
 Administration of Mimetix, Inc., a woman's healthcare pharmaceutical company,
 and as Vice President, Finance and Treasurer of Sequus Pharmaceuticals, Inc.,
 an oncology and infectious disease pharmaceutical company.  Stewart is a
 certified public accountant with a B.S. degree in Accounting from San
 Francisco State University and an MBA from Santa Clara University.
     "We are very pleased to bring Don onto our executive team," commented
 Barry Cheskin, RITA's President and Chief Executive Officer.  "Don brings a
 wealth of financial, operational and investor relations expertise to the
 Company, and we look forward to his contributions to our continued success."
     RITA Medical Systems develops, manufactures and markets innovative
 products for patients with solid cancerous or benign tumors.  The proprietary
 RITA(R) system uses radiofrequency energy to heat tissue to a high enough
 temperature to ablate it or cause cell death.  While the company's current
 focus is on liver cancer, the company believes that its minimally invasive
 technology may in the future be applied to other types of tumors, including
 tumors of the lung, bone, breast, prostate and kidney.  The company has
 received regulatory clearance in major markets worldwide, including the
 United States.  In March 2000, RITA became the first radiofrequency ablation
 company to receive specific FDA clearance for unresectable liver lesions in
 addition to its previous general FDA clearance for the ablation of soft
 tissue.  The company has sold over 20,000 of its disposable devices throughout
 the world.
     The statements in this news release related to the company's plan to
 extend the technology to applications beyond the liver are forward-looking
 statements involving risks and uncertainties that could cause actual results
 to differ materially from those in such forward-looking statements.  Further
 information regarding these and other risks is included in the company's S-1
 registration statement and other recent filings with the Securities and
 Exchange Commission, including the company's Report on Form 10-K for the year
 ended December 31, 2000 and Reports on Form 10-Q for the periods ended
 September 30, 2000 and June 30, 2000.
     NOTE:  RITA is a registered trademark of RITA Medical Systems, Inc.
 
 

SOURCE RITA Medical Systems, Inc.
    MOUNTAIN VIEW, Calif., April 16 /PRNewswire/ --
 RITA Medical Systems, Inc. (Nasdaq: RITA) today announced that
 Donald J. Stewart has joined the company as Vice President,
 Finance & Administration and Chief Financial Officer.  Stewart will report
 directly to Barry Cheskin, RITA's President and Chief Executive Officer.
 Earlier this year the Company announced Marilynne Solloway's intention to
 retire and the initiation of a search for her replacement, and the Company is
 pleased to announce the successful outcome of that search.
     Stewart comes to RITA from Abaxis, Inc., a medical device company
 manufacturing point-of-care blood analysis systems.  Stewart spent three years
 at Abaxis as Vice President, Finance & Administration, Chief Financial Officer
 and Secretary.  Previously he served as Vice President, Finance &
 Administration of Mimetix, Inc., a woman's healthcare pharmaceutical company,
 and as Vice President, Finance and Treasurer of Sequus Pharmaceuticals, Inc.,
 an oncology and infectious disease pharmaceutical company.  Stewart is a
 certified public accountant with a B.S. degree in Accounting from San
 Francisco State University and an MBA from Santa Clara University.
     "We are very pleased to bring Don onto our executive team," commented
 Barry Cheskin, RITA's President and Chief Executive Officer.  "Don brings a
 wealth of financial, operational and investor relations expertise to the
 Company, and we look forward to his contributions to our continued success."
     RITA Medical Systems develops, manufactures and markets innovative
 products for patients with solid cancerous or benign tumors.  The proprietary
 RITA(R) system uses radiofrequency energy to heat tissue to a high enough
 temperature to ablate it or cause cell death.  While the company's current
 focus is on liver cancer, the company believes that its minimally invasive
 technology may in the future be applied to other types of tumors, including
 tumors of the lung, bone, breast, prostate and kidney.  The company has
 received regulatory clearance in major markets worldwide, including the
 United States.  In March 2000, RITA became the first radiofrequency ablation
 company to receive specific FDA clearance for unresectable liver lesions in
 addition to its previous general FDA clearance for the ablation of soft
 tissue.  The company has sold over 20,000 of its disposable devices throughout
 the world.
     The statements in this news release related to the company's plan to
 extend the technology to applications beyond the liver are forward-looking
 statements involving risks and uncertainties that could cause actual results
 to differ materially from those in such forward-looking statements.  Further
 information regarding these and other risks is included in the company's S-1
 registration statement and other recent filings with the Securities and
 Exchange Commission, including the company's Report on Form 10-K for the year
 ended December 31, 2000 and Reports on Form 10-Q for the periods ended
 September 30, 2000 and June 30, 2000.
     NOTE:  RITA is a registered trademark of RITA Medical Systems, Inc.
 
 SOURCE  RITA Medical Systems, Inc.